An implantable anticancer device (IAD) amenable to eradicate local regional recurrence (LRR) of breast cancer as well as to enhance the breast reconstruction during/after therapy is proposed for the first time. The IAD is fabricated by incorporating the superparamagnetic graphene oxide doxorubicin nanocomposite of size ≈200 nm in a nanofiber matrix to enable the sustained and tumor specific anticancer drug release over 60 d in vitro with a minimum initial burst release and the repeated hyperthermic capability in an alternating magnetic field to ensure the synergistic inhibition of LRR. The IAD also enriches the reconstruction of poor breast cosmesis that resulted from the surgical treatment by supporting the lipofilling of the surgical residual cavity to induce the adipogenic process. Moreover, the noninvasive monitoring capability of IAD through magnetic resonance imaging augments to the effective patient care. Thus, this work reports a new and reliable concept by introducing the multifunctional IAD possessing enhanced specificity with a real-time monitoring capability and long-term anticancer efficacy as a potential platform for synergistic inhibition of LRR and a great promise for the in situ breast reconstruction ability for better breast cosmesis.